Skip to main content

Advertisement

SpringerLink
Log in

Antibody therapy of non-Hodgkin's B-cell lymphoma

  • Symposium in Writing
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract.

Engineering antibodies with reduced immunogenicity and enhanced effector functions, and selecting antigen targets with the appropriate specificity, density, and/or functionality, have contributed to the recent clinical successes in using unconjugated "naked" antibody therapies of B-cell lymphoma (rituximab) and breast carcinoma (Herceptin). The non-overlapping toxicities of naked antibodies and chemotherapy, together with their potential synergy, which is based on unique and complementary mechanisms of action, have contributed to the creation of new standards of care in cancer therapy and management. Clinical trial results supporting these concepts are presented. Furthermore, the exquisite specificity of antibodies renders them ideal vehicles for selective delivery of toxic payloads such as drugs or radionuclides. Although successful in therapy of hematological cancers (Zevalin, Mylotarg), the broader application of these technologies to carcinomas still remains to be proven in clinical testing. Engineering of antibody constructs with optimal blood clearance and tumor-targeting kinetics, and selecting the radionuclide that may deliver sufficient radiation energy to kill the more radio-resistant carcinomas, are discussed. With the advent of genomics and proteomics, new membrane-associated tumor antigens are being discovered and will provide novel targets for future antibody therapy of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.

Similar content being viewed by others

References

  1. IDEC Pharmaceuticals Corporation (2001) Rituxan (rituximab). IDEC Pharmaceuticals Corporation, San Diego, vol 19, p 2

  2. U.S. Food and Drug Administration Center for Biologics Evaluation and Research (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use. J Immunother 20:214–243

    PubMed  Google Scholar 

  3. IDEC Pharmaceuticals Corporation (1996) A phase I/II clinical trial of yttrium-[90]-labeled IDEC-2B8 given every 6 to 8 weeks to patients with B-cell lymphoma. BB-IND 4850 and 4851. IDEC Pharmaceuticals Corporation, San Diego, vol 106-01-01

  4. IDEC Pharmaceuticals Corporation (2000) A phase II, open-label, multicenter trial to evaluate the safety and efficacy of IDEC-Y2B8 radioimmunotherapy of relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma in patients with mild thrombocytopenia. IDEC Pharmaceuticals Corporation, San Diego, vol 106-05

  5. IDEC Pharmaceuticals Corporation (2000) A phase III, open-label, nonrandomized controlled, multicenter trial to evaluate the safety and efficacy of IDEC-Y2B8 radioimmunotherapy in patients with B-cell non-Hodgkin's lymphoma who are refractory to prior rituximab therapy. IDEC Pharmaceuticals Corporation, San Diego

  6. Alas S, Bonavida B, Emmanouilides C (2000) Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 20:2961–2966

    CAS  PubMed  Google Scholar 

  7. Alas S, Emmanouilides C, Bonavida B (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709–723

    CAS  PubMed  Google Scholar 

  8. Anderson WT, Strand M (1987) Radiolabeled antibody: iodine versus radiometal chelates. J Natl Cancer Inst Monogr 3:149–151

    Google Scholar 

  9. Austin AL, Ellender M, Haines JW, Harrison JD, Lord BI (2000) Microdistribution and localized dosimetry of the alpha-emitting radionuclides 239Pu, 241Am and 233U in mouse femoral shaft. Int J Radiat Biol 76:101–111

    Article  CAS  PubMed  Google Scholar 

  10. Aviles A, Talavera A, Diaz-Maqueo JC, Garcia EL, Cleto S, Neri N (2001) Evaluation on a six-dose treatment of anti CD20 monoclonal antibody in patients with refractory follicular lymphoma. Cancer Biother Radiopharm 16:159–162

    Article  CAS  PubMed  Google Scholar 

  11. Barnett RS, Limoli KL, Huynh TB, Ople EA (1995) Antibody production in Chinese hamster ovary cells using an impaired selectable marker. In: Wang HY, Imanaka T (eds) Antibody expression and engineering. American Chemical Society, Washington D.C., pp 27–40

  12. Beatty BG, Kuhn JA, Hui TE, Fisher DR, Williams LE, Beatty JD (1994) Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate. Cancer 73 (Suppl):958–965

    Google Scholar 

  13. Berger MJ (1971) Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. J Nucl Med 13 (Suppl 5):5–23

    Google Scholar 

  14. Brechbiel MW, Gansow OA (1991) Backbone-substituted DTPA ligands for90Y radioimmunotherapy. Bioconjug Chem 2:187–194

    CAS  PubMed  Google Scholar 

  15. Brekke OH, Michaelsen TE, Aase A, Sandin RH, Sandlie I (1994) Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis. Eur J Immunol 24:2542–2547

    CAS  PubMed  Google Scholar 

  16. Buchsbaum DJ (1995) Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In: Goldenberg DM (ed) Cancer therapy with radiolabelled antibodies. CRC Press, Boca Raton, Florida, p 115

  17. Buchsbaum DJ, Langmuir VK, Wessels BW (1993) Experimental radioimmunotherapy. Med Phys 20:551–567

    CAS  PubMed  Google Scholar 

  18. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL (2002) Combined modality radioimmunotherapy. Promise and peril. Cancer 94 (Suppl):1320–1331

    CAS  PubMed  Google Scholar 

  19. Burton DR, Woof JM (1992) Human antibody effector function. Adv Immunol 51:1–84

    CAS  PubMed  Google Scholar 

  20. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153–2164

    CAS  PubMed  Google Scholar 

  21. Byrd JC, Peterson BL, Park K, Morrison V, Vardiman JW, Jacobson R, Rai K, Larson RA (2001) Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic lymphoma (CLL) patients: results from CALGB 9712. The 43rd Annual Meeting of the American Society of Hematology (ASH), Orlando, Florida, 7–11 December. Blood 98:772a, no. 3212

    Google Scholar 

  22. Cabanillas F, McLaughlin P, Hagemeister F, Rodriquez MA, Romaguera JE, Younes A, Sarris AH, Pro B, Dang N, Samaniego F, Lee MS (2000) Molecular responses with FND+rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin's lymphoma. Blood 96:331a

    Google Scholar 

  23. Cardillo TM, Blumenthal R, Ying Z, Gold DV (2002) Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer 97:386–392

    Article  CAS  PubMed  Google Scholar 

  24. Caron PC, Schwartz MA, Co MS, Queen C, Finn RD, Graham MC, Divgi CR, Larson SM, Scheinberg DA (1994) Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer 73 (Suppl):1049–1056

    Google Scholar 

  25. Cassatt DR, Fazenbaker CA, Bachy CM, Hanson MS (2002) Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin Radiat Oncol 121 (Suppl 1):97–102

    Article  Google Scholar 

  26. Ceriani RL, Blank EW, Peterson JA, Battifora H, Singh H (1990) Immunotherapeutic preclinical evaluation of anti-human milk fat globule MoAbs Mc5 and BrE-1. Antib Immunoconjug Radiopharm 3:181

    Google Scholar 

  27. Chakrabarti MC, Le N, Paik CH, DeGraff WG, Carrasquillo JA (1996) Prevention of radiolysis of monoclonal antibody during labeling. J Nucl Med 37:1384–1388

    CAS  PubMed  Google Scholar 

  28. Chaouchi N, Vazquez A, Galanaud P, Leprince C (1995) B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. J Immunol 154:3096–3104

    CAS  PubMed  Google Scholar 

  29. Chemnitz J, Daube A, Schulz A, Scheid C, Fuchs M, Diehl V, Sohngen D (2001) Rituximab in the treatment of severe thrombocytopenic purpura (TTP). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:33a, no. 131

    Google Scholar 

  30. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Conners JM, Lister TA, Vose J, Grillo-López AJ, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244–1253

    CAS  PubMed  Google Scholar 

  31. Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR (1999) Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 15:1017–1025

    CAS  PubMed  Google Scholar 

  32. Chinn PC, Morena RA, Wakefield M, Wiseman GA, Zimmer M, Silverman DH, Bartlett NL, Spies S, Witzig TE, Grillo-López AJ, White CA (2001) Nuclear pharmacy and nuclear medicine clinical experience preparing radiolabled Zevalin™ (IDEC-Y2B8 and IDEC-IN2B8) using a radiolabeling cold kit. The 48th Annual Meeting of the Society of Nuclear Medicine, Toronto, Ontario, Canada, 23–27 June. J Nucl Med 42 (Suppl):265P, no. 1115

    Google Scholar 

  33. Chowdhury PS,Pastan I (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 17:568–572

    Article  CAS  PubMed  Google Scholar 

  34. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM (2000) Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 6:3621–3628

    CAS  PubMed  Google Scholar 

  35. Coiffier B (1998) Monoclonal anti-CD20 antibody in mantle cell lymphoma and diffuse large B-cell lymphoma. Ann Hematol 77 (Suppl 1):A7

    Google Scholar 

  36. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F (1998) Rituximab (Anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927–1932

    CAS  PubMed  Google Scholar 

  37. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P,Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    CAS  PubMed  Google Scholar 

  38. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamotoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Theiblemont C, Montestruc F, Mathieu-Boue A, Benzohra A, Solal-Celigny P (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101–106

    Article  CAS  PubMed  Google Scholar 

  39. Conconi A, Thiéblemont C, Martinelli G, Ferreri AJM, Devizzi L, Peccatori F, Ponzoni M, Filipazzi V, Dietrich P, Gianni MA, Cavalli F, Zucca E (2001) Activity of rituximab in extranodal marginal zone lymphomas (MALT-Type). The 43rd Annual Meeting of American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:3354

    Article  Google Scholar 

  40. Cooper N, Bussel J (2001) Rituxan treatment in patients with immune thrombocytopenic purpura (ITP). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:521a, no. 2180

    Google Scholar 

  41. Czuczman M (2001) Progression free survival (PFS) after six years (median) follow-up of the first clinical trial of rituximab/CHOP chemoimmunotherapy. The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:601a, no. 2519

    Google Scholar 

  42. Czuczman M, Fallon A, Mohr A, Stewart C, Klippenstein D, Loud P, Lamonica D, Bernstein ZP, McCarthy PL, Skipper M, Brown K, Miller K, Wentling D, Rock M, Benyunes K, Grillo-Lopez AJ, Bernstein SJ (2001) Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma (LGL): final report. The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:601a, no. 2518

    Google Scholar 

  43. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippensten D, Dallaire BK, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276

    PubMed  Google Scholar 

  44. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio F, Jonas C, Klippenstein D, Dallaire B, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276

    PubMed  Google Scholar 

  45. Czuczman MS, Fallon A, Scarpace A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Rock MK, Benyunes M, Grillo-López A, Bernstein SH (2000) Phase II study of rituximab in combination with fludarabine in patients with low-grade or follicular B-cell lymphoma. Blood 96:729a

    Google Scholar 

  46. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M (2001) Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 74:288–294

    Article  CAS  PubMed  Google Scholar 

  47. Davis TA, Grillo-López AJ, McLaughlin P, Alkuzweny B, Weaver RL, White CA (2000) Repeated treatments (ReRx) with rituximab in patients with relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (LG/F NHL) provide longer response duration (DR) compared to prior chemotherapy (CRx). The 42nd Annual Meeting of the American Society of Hematology, San Francisco, 1–5 Dec. Blood 96:235b, no. 4748

    Google Scholar 

  48. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135–3143

    CAS  PubMed  Google Scholar 

  49. Davis TA, White CA, Grillo-López AJ, Velásquez WS, Link BK, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 17:1851–1857

    CAS  PubMed  Google Scholar 

  50. Delgado J, Bustos JG, Jimenez-Yuste V, Garcia B, de Paz R, Garcia J, Villar A, Quintana M, Hernandez-Navarro F (2001) Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:59b, no. 3851

    Google Scholar 

  51. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B (1997) Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177–185

    CAS  PubMed  Google Scholar 

  52. DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP, O'Grady LF, Raventos A, Kroger LA, Macey DJ, McGahan JP, Mills SL, Shen S (1998) Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131-LYM-1 antibody. Cancer Biother Radiopharm 13:239–254

    CAS  PubMed  Google Scholar 

  53. DeNardo GL, DeNardo SJ, Wessels BW, Kukis DL, Miyao N, Yuan A (2000) 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis. Cancer Biother Radiopharm 15:547–560

    CAS  PubMed  Google Scholar 

  54. DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ (1998) Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. Clin Cancer Res 4:2483–2490

    CAS  PubMed  Google Scholar 

  55. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ (2002) Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94 (Suppl):1332–1348

    CAS  PubMed  Google Scholar 

  56. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N (2002) Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 20:2327–2333

    Article  CAS  PubMed  Google Scholar 

  57. Ekstrand BC, Lucas JB, Horwitz SM, Breslin S, Bartlett NL, Hoppe RT, Horning SJ (2002) Rituximab in lymphocyte predominant Hodgkin's disease (LPHD): results of a phase II trial. The 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, 18–21 May. Blood 21:264a, no. 1052

    Google Scholar 

  58. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, Rohrlich P, Peuchmaur M, Matthieu-Boue A, Fischer A, Vilmer E (2001) Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 115:112–118

    Article  CAS  PubMed  Google Scholar 

  59. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1994) A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 5 (Suppl 2):91–95

    Google Scholar 

  60. Foran JM, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M, Johnson PW, Gisselbrecht C, Bradburn M, Matthews J, Lister TA (2000) Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 11 (Suppl 1):S117–S121

    Article  Google Scholar 

  61. Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PW, Bessell E, Hancock B, Summers K, Hughes J, Rohatiner AZS, Lister TA (2000) A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 109:81–88

    Article  CAS  PubMed  Google Scholar 

  62. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317–324

    CAS  PubMed  Google Scholar 

  63. Gansow O (1991) Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl Med Biol 18:369–381

    CAS  Google Scholar 

  64. Garcia Manero G (2001) Update of results of the combination of Fludarabine, cyclophosphamide, and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:633a, no. 2650

    Google Scholar 

  65. Ghielmini M, Hsu-Schmitz SF, Bürky K, Pichert G, Betticher D, Stupp R, Wernli M, Herrmann R, Schmitter D, Zucca E, Cerny T (1999) The effect of rituximab on patients with follicular and mantle cell lymphoma. Ann Oncol 10 (Suppl):33

    CAS  Google Scholar 

  66. Ghielmini M, Schmitz S-FH, Cogliatti SB, Pichert G, Fey M, Betticher D, Martinelli G, Peccatori F, Hess U, Stahel R, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T (2002) Maintenance treatment with 2-monthly rituximab after standard weekly × 4 Rituximab induction significantly improves event-free survival in patients with follicular lymphoma. Ann Oncol 13 (Suppl 2):38, 112

    Article  Google Scholar 

  67. Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL (1981) Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 41:4354–4360

    CAS  PubMed  Google Scholar 

  68. Gregory SA, Venugopal P, Adler SS, O'Brien TM, O'Donnell KF, Yunus F (2001) Safety and efficacy of fludarabine and mitoxantrone with rituximab consolidation in untreated advanced low-grade non-Hodgkin's lymphoma (LG-NHL). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:605a, no. 2534

    Google Scholar 

  69. Griffiths GL (1995) In: Goldenberg DM (ed) Radiochemistry of therapeutic radionuclides. Cancer therapy with radiolabelled antibodies. CRC Press, Boca Raton, Florida, p 47

  70. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M (2002) Rituximab: ongoing and future clinical development. Semin Oncol 29 (Suppl 2):105–112

    Article  CAS  PubMed  Google Scholar 

  71. Grillo-López AJ, Shen D, Lee D, Dallaire BK, Dowden S, White CA (2000) Rituximab: sustained remissions in patients with relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (LG/NHL). The 42nd Annual Meeting of the American Society of Hematology, San Francisco. Blood 96:238b, no. 4760

    Google Scholar 

  72. Gupta NK, Kavuru S, Patel D, Driscoll N, Janson D, Prasad B, Rai KR (2002) Long-term results from a monthly regimen of rituximab (R), cyclophosphamide (C), and dexamethosone (D) in advanced chronic lymphocytic leukemia (CLL). The 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, 18–21 May, 21:275a, no. 1098

  73. Gupta NK, Patel D, Kavuru S, Driscoll N, Janson D, Ahmed I, Rai K (2001) Re-treatment with a rituximab-based therapy is highly effective in autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia (CLL). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:363a, no. 1529

    Google Scholar 

  74. Gutheil JC, Finucane D, Rodriquez F, Saleh F, Stahler S, Royston I (2000) Phase II study of rituximab (Rituxan) in patients with previously untreated low-grade or follicular non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol, New Orleans,19:22a, no. 79

  75. Hainsworth JD (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 29 (Suppl 2):25–29

    Article  CAS  Google Scholar 

  76. Hainsworth JD, Burris HA, Yardley DA, Litchey S, Morrissey LH, Grimaldi M, McCarthy M, Greco FA (2002) Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma (NHL): a Minnie Pearl Cancer Research Network phase II trial. The 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, 7–11 December, 21:268a, no. 1070

  77. Hainsworth JD, Burris III HA, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD III, Richards P, Greco FA (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052–3056

    CAS  PubMed  Google Scholar 

  78. Hainsworth JD, Litchy S, Burris HA, Greco FA (2001) Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:363a, no. 1530

    Google Scholar 

  79. Harrison A, Walker CA, Parker D, Jankowski KJ, Cox JPL, Craig AS, Sansom JM, Beeley NRA, Boyce RA, Chaplin L, Eaton MAW, Farnsworth APH, Millar K, Millican AT, Randall AM, Rhind SK, Secher DS, Turner A (1991) The in vivo release of90Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med Biol 18:469–476

    CAS  Google Scholar 

  80. Harwood SJ, Gibbons LK, Goldner PJ, Webster WB, Carroll RG (2002) Outpatient radioimmunotherapy with Bexxar. Closed, clean air reservoir minimizes personnel radiation exposure. Cancer 94 (Suppl):1358–1362

    CAS  PubMed  Google Scholar 

  81. Herold M, Fiedler F, Pasold R, Knauf W, Freund M, Naumann R, Rohrberg R, Gruenhagen U von, Klinkenstein C, Gericke U, Franke A, Kaiser U, Niederweiser D, Steglich J, Clemens M-R, Kettner E, Mey U, Richter P, Hoffman F A, Bremer K, Doelken G, Eschenburg H, Hahnfeld S, Haak U, Lakner V, Subert R (2001) Efficacy and toxicity of rituximab plus mitoxantrone, chlorambucil, prednisolone (MCP) versus MCP alone in advanced indolent NHL—interim results of a clinical phase III study of the East German Study Group Hematology/Oncology (OSHO). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:601a, no. 2521

    Google Scholar 

  82. Hiddemann W, Forstpointner R, Fiedler F, Gramatzki M, Dorken B, Illiger H-J, Kneba M, Pfreundschuh M, Parsold R, Parwaresch R, Dreyling M, Unterhalt M (2001) The addition of Rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL): results of a prospective randomized comparison of the German Low Grade Study Group (GLSG). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:844a, no. 3507

    Google Scholar 

  83. Horwitz SM, Tsai D, Twist C, Sarwal M, Breslin S, Dahl G, Stadtmauer E, Horning S (2001) Rituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: a prospective trial in adults and children. Proc Am Soc Clin Oncol, San Francisco, 20:284a, no. 1134

  84. Hosono M, Endo K, Sakahara H, Watanabe Y, Saga T, Nakai T, Kawai C, Matsumori A, Yamada T, Watanabe T, Konishi J (1992) Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA). Br J Cancer 65:197–200

    CAS  PubMed  Google Scholar 

  85. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288–1294

    Article  CAS  PubMed  Google Scholar 

  86. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM (1996) Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56:3055–3061

    CAS  PubMed  Google Scholar 

  87. Huhn D, Schilling C von, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326–1331

    Article  CAS  PubMed  Google Scholar 

  88. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG (2000) Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164:4178–4184

    CAS  PubMed  Google Scholar 

  89. Igarashi T, Itoh K, Kobayashi Y, Ogura M, Kinoshita T, Taniwaki M, Hiraoka A, Hotta T, Aikawara K, Tsushita K, Tobinai K (2002) Phase II and pharmacokinetic study of Rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin's lymphoma (B-NHL). The 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, 18–21 May, 21:286a, no. 1142

  90. Jazirehi AR, Bonavida B, Emmanouilides CE (2000) Rituximab sensitizes non-Hodgkin's lymphoma B cell lines to taxol-mediated cytotoxicity and synergy is achieved in both apoptosis and necrosis. Blood 96:131a

    Google Scholar 

  91. Jowsey J (1958) The deposition of rare earths in bone. Radiat Res 8:490

    CAS  Google Scholar 

  92. Junghans RP (1997) Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 16:29–57

    CAS  PubMed  Google Scholar 

  93. Keating MJ, O'Brien S, Lerner S, Giles F, Andreeff M, Cortes J, Albitar M, Kantarjian H (2000) Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL). Blood 96:514a

    Google Scholar 

  94. Kennel SJ, Brechbiel MW, Milenic DE, Schlom J, Mirzadeh S (2002) Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49. Cancer Biother Radiopharm 17:219–231

    Article  CAS  PubMed  Google Scholar 

  95. Kennel SJ, Mirzadeh S, Eckelman WC, Waldmann TA, Garmestani K, Yordanov AT, Stabin MG, Brechbiel MW (2002) Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At. Radiat Res 157:633–641

    CAS  PubMed  Google Scholar 

  96. Kewalramani T, Zelenetz A, Bertino J, Donnelly G, Hedrick E, O'Connor O, Portlock C, Straus D, Yahalom J, Gencarelli A, Remy D, Qin J, Nimer S, Moskowitz C (2001) Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December, 98:346a, no. 1459

  97. Khazaeli MB, Forero A, Meredith RF, Shen S, Carpenter M, Liu W, Schlom J, LoBoglio A (2002) An improved monoclonal antibody design for radioimmunotherapy (RIT). American Association for Cancer Research 93rd Annual Meeting, San Francisco, 6–10 April. Proc Am Assoc Cancer Res 43:1015, no. 5026

    Google Scholar 

  98. Kievit E, Pinedo HM, Schluper HM, Boven E (1997) Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int J Radiat Oncol Biol Phys 38:419–428

    Article  CAS  PubMed  Google Scholar 

  99. Kinuya S, Yokoyama K, Tega H, Hiramatsu T, Konishi S, Yamamoto W, Shuke N, Aburano T, Watanabe N, Takayama T, Michigishi T, Tonami N (1998) Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice. Jpn J Cancer Res 89:870–878

    CAS  PubMed  Google Scholar 

  100. Kishore R, Eary JF, Krohn KA, Nelp WB, Menard TW, Beaumier PL, Hellstrom KE, Hellstrom I (1986) Autoradiolysis of iodinated monoclonal antibody preparations. Int J Radiat Appl Instrum B 13:457–459

    CAS  Google Scholar 

  101. Knox SJ, Levy R, Miller RA, Uhland W, Schiele J, Ruehl W, Finston R, Day-Lollini P, Goris ML (1990) Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 50:4935–4940

    CAS  PubMed  Google Scholar 

  102. Kobayashi H, Wu C, Yoo TM, Sun BF, Drumm D, Pastan I, Paik CH, Gansow OA, Carrasquillo JA, Brechbiel MW (1998) Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J Nucl Med 39:829–836

    CAS  PubMed  Google Scholar 

  103. Kohler G, Milstein C (1975) Continuous cultures of fused secreting antibody of redefined specificity. Nature 256:495–497

    PubMed  Google Scholar 

  104. Kozak RW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghans RP, Gansow OA, Waldmann TA, Junghaus R (1989) Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res 49:2639–2644

    CAS  PubMed  Google Scholar 

  105. Kvinnsland Y, Stokke T, Aurlien E (2001) Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res 155:288–296

    CAS  PubMed  Google Scholar 

  106. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77–89

    PubMed  Google Scholar 

  107. Liu S, Cheung E, Ziegler MC, Rajopadhye M, Edwards DS (2001) (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug Chem 12:559–568

    Article  CAS  PubMed  Google Scholar 

  108. Liu S, Pietryka J, Ellars CE, Edwards DS (2002) Comparison of yttrium and indium complexes of DOTA-BA and DOTA-MBA: models for (90)Y- and (111)In-labeled DOTA-biomolecule conjugates. Bioconjug Chem 13:902–913

    Article  CAS  PubMed  Google Scholar 

  109. Loeevinger R, Berman M (1968) A schema for absorbed-dose calculations for biologically distributed radionuclides. J Nucl Med (Suppl 1):9–14

    Google Scholar 

  110. Lucas JB, Hoppe RT, Horwitz SM, Breslin S, Horning SJ (2000) Rituximab is active in lymphocyte predominance Hodgkin's disease. Blood 96:831a

    Google Scholar 

  111. Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, Brechbiel MW, Scheinberg DA (2002) Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 16:60–66

    Article  CAS  PubMed  Google Scholar 

  112. Maisin JR (1989) Chemical protection against ionizing radiation. Adv Space Res 9:205–212

    Article  CAS  PubMed  Google Scholar 

  113. Maloney D, Press OW, Braziel RM, Unger JM, LeBlanc M, Grogan TM, Miller TP, Fisher RI (2001) A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800. The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:843a, no. 3502

    Google Scholar 

  114. Mardirossian G, Wu C, Hnatowich DJ (1993) The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators. Nucl Med Biol 20:65–74

    CAS  PubMed  Google Scholar 

  115. Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY (2000) Anti-CD20 and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 60:7170–7176

    CAS  PubMed  Google Scholar 

  116. Mayer R, Dillehay LE, Shao Y, Song S, Zhang YG, Bartholomew RM, Williams JR (1994) A new method for determining dose rate distribution from radioimmuno-therapy using radiochromic media. Int J Radiat Oncol Biol Phys 28:505–513

    CAS  PubMed  Google Scholar 

  117. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    CAS  PubMed  Google Scholar 

  118. McLaughlin P, Hagemeister FB, Grillo-López AJ (1999) Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 2 (Suppl 14):79–87

    Google Scholar 

  119. McMurry TJ, Pippin CG, Wu C, Deal KA, Brechbiel MW, Mirzadeh S, Gansow OA (1998) Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates. J Med Chem 41:3546–3549

    Article  CAS  PubMed  Google Scholar 

  120. Mehta MP, Kubsad SS, Fowler JF, Verma AK, Hsieh JT, Kinsella TJ (1990) 90Y.B72.3 against pancreatic cancer: dosimetric and biological analysis. Int J Radiat Oncol Biol Phys 19:627–631

    CAS  PubMed  Google Scholar 

  121. Meredith R, Khazaeli M, Plott W, Saleh M, Liu T, Allen L (1992) Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 33:23–29

    CAS  PubMed  Google Scholar 

  122. Meredith RF, Khazaeli MB, Plott WE, Brezovich IA, Russell CD, Wheeler RH, Spencer SA, LoBuglio AF (1992) Comparison of two mouse/human chimeric antibodies in patients with metastatic colon cancer. Antibody Immunoconj Radiopharm 5:75–80

    Google Scholar 

  123. Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517–522

    CAS  PubMed  Google Scholar 

  124. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851–6855

    CAS  PubMed  Google Scholar 

  125. Morrison VA, Bartlett N, Dunn DL, Peterson A (2001) Rituximab therapy for post-transplant lymphoproliferative disorders (PTLD): preliminary outcome results. Proc Am Soc Clin Oncol, San Francisco, 20:295a, no. 1177

  126. Newell MK, VanderWall J, Beard KS, Freed JH (1993) Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc Natl Acad Sci USA 90:10459–10463

    CAS  PubMed  Google Scholar 

  127. Newman R, Alberts J, Anderson D, Carner K, Heard C, Norton F, Raab R, Reff M, Shuey S, Hanna N (1992) "Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology 10:1455–1460

    CAS  PubMed  Google Scholar 

  128. Nourigat C, Badger CC, Bernstein ID (1990) Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst 82:47–50

    CAS  PubMed  Google Scholar 

  129. O'Brien S, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165–2170

    CAS  PubMed  Google Scholar 

  130. O'Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL, Meyers FJ (2002) Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate 50:27–37

    Article  CAS  PubMed  Google Scholar 

  131. Patel D, Gupta NK, Mehrotra B, Russo L, Driscoll N, Gor A, Padmanabhan S, Miller N,Rai K R (2001) Rituximab,cyclophosphamide and decadron (RCD) combination is an effective salvage regimen for previously treated low grade lymphoma. Proceedings of the American Society of Clinical Oncology, San Francisco, CA.;20(2):228b, 2665.

  132. Pavlinkova G, Booth BJ, Batra SK, Colcher D (1999) Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clin Cancer Res 5:2613–2619

    CAS  PubMed  Google Scholar 

  133. Pedley RB, Begent RH, Boden JA, Boxer GM, Boden R, Keep PA (1994) Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model. Int J Cancer 57:830–835

    CAS  PubMed  Google Scholar 

  134. Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V (1999) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655–661

    Article  CAS  PubMed  Google Scholar 

  135. Poretta TA, Devereux L, Grana G, Hageboutros A, Sbar E, Patibandla S, O'Brien A, Goldberg J (2001) Rituximab, cyclophosphamide, and dexamethasone provide hematologic and immunologic response in patients with relapsed refractory chronic lymphocytic leukemia and associated autoimmune activity. Proc Am Soc Clin Oncol, San Francisco, 20(2):225b, no. 2650

    Google Scholar 

  136. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86:10029–10033

    CAS  PubMed  Google Scholar 

  137. Quinones HI, List AF, Gerner EW (2002) Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives. Clin Cancer Res 8:1295–3000

    CAS  PubMed  Google Scholar 

  138. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    CAS  PubMed  Google Scholar 

  139. Reff ME, Hariharan K, Braslawsky G (2002) Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 9:152–166

    PubMed  Google Scholar 

  140. Risse JH, Ponath C, Palmedo H, Menzel C, Grunwald F, Biersack HJ (2001) Radiation exposure and radiation protection of the physician in iodine-131 Lipiodol therapy of liver tumours. Eur J Nucl Med 28:914–918

    Article  CAS  PubMed  Google Scholar 

  141. Roberson PL, Buchsbaum DJ (1995) Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with131iodine-labeled antibody for a colon cancer model. Cancer Res 55 (Suppl):5811s–5816 s

    CAS  PubMed  Google Scholar 

  142. Roberson PL, Dudek S, Buchsbaum DJ (1997) Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. Cancer 80 (Suppl):2567–2575 [pii]

    Article  CAS  PubMed  Google Scholar 

  143. Roselli M, Schlom J, Gansow OT, Brechbiel MW, Mirzadeh S, Pippin CG, Milenic DE, Colcher D (1991) Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. Nucl Med Biol 18:389–394

    CAS  Google Scholar 

  144. Salako QA, O'Donnel RT, DeNardo SJ (1998) Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations. J Nucl Med 39:667–670

    CAS  PubMed  Google Scholar 

  145. Saleh MN, Moore M, Feinberg B, Bunch P, Butler J, Lavelle P, Kunkel L, Benyunes K, Grillo-Lopez AJ, LoBoglio A (2001) A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura (ITP). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:521a, no. 2179

    Google Scholar 

  146. Sautter-Bihl ML, Wessely R, Bihl H (1993) Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts. Strahlenther Onkol 169:595–600

    CAS  PubMed  Google Scholar 

  147. Schlom J, Colcher D, Siler K, Thor A, Bryant G, Johnston WW, Szpak CA, Sugarbaker P, Carrasquillo JA, Reynolds JC et al. (1990) Tumor targeting with monoclonal antibody B72.3: experimental and clinical results. Cancer Treat Res 51:313–335

    CAS  PubMed  Google Scholar 

  148. Schultz J, Lin Y, Sanderson J, Zuo Y, Stone D, Mallett R, Wilbert S, Axworthy D (2000) A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res 60:6663–6669

    CAS  PubMed  Google Scholar 

  149. Schulz H, Klein SK, Rehwald U, Reiser M, Ibach S, Aulitzky E, Hensel M, Herold M, Huhn D, Knauf U, Hallek M, Diehl V, Engert A (2001) Phase-II study of rituximab in combination with fludarabine in patients with chronic lymphocytic leukemia (CLL). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:364a, no. 1534

    Google Scholar 

  150. Schumacher C, Paul K, Robbe Y, Sicart MT, Chanal JL, Delard R, Dubois JB (1997) Mice's rectum radioprotection: comparative efficacy of a series of aminothiols and aminothiol precursors. Farmaco 52:729–731

    CAS  PubMed  Google Scholar 

  151. Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673–683

    CAS  PubMed  Google Scholar 

  152. Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644–1652

    CAS  PubMed  Google Scholar 

  153. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM (1990) Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 50:2330–2336

    CAS  PubMed  Google Scholar 

  154. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591–6604

    CAS  PubMed  Google Scholar 

  155. Slavin-Chiorini DC, Horan Hand P, Kashmiri SVS, Calvo B, Zaremba S, Schlom J (1993) Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. Int J Cancer 53:97–103

    CAS  PubMed  Google Scholar 

  156. Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH (1997) A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 12:305–316

    CAS  PubMed  Google Scholar 

  157. Snyder WS, Ford MR, Warner GG, Watson SB (1975) "S," absorbed dose per unit cumulated activity for selected radionuclides and organs Medical Internal Radiation Dose (MIRD) pamphlet 11

  158. Solal-Celigny P (2001) Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden. Anti Cancer Drugs 12:S11–S14

    CAS  Google Scholar 

  159. Srinivasan V, Pendergrass JA Jr, Kumar KS, Landauer MR, Seed TM (2002) Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. Int J Radiat Biol 78:535–543

    Article  CAS  PubMed  Google Scholar 

  160. Stabin MG (1996) MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37:538–546

    CAS  PubMed  Google Scholar 

  161. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952–957

    Article  CAS  PubMed  Google Scholar 

  162. Stein R, Blumenthal R, Sharkey RM, Goldenberg DM (1994) Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts. Cancer 73 (Suppl 3):816–823

    Google Scholar 

  163. Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W (2001) Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis 60:892–893

    CAS  PubMed  Google Scholar 

  164. Tao MH, Morrison SL (1989) Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143:2595–2601

    CAS  PubMed  Google Scholar 

  165. Tao MH, Smith RI, Morrison SL (1993) Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 178:661–667

    CAS  PubMed  Google Scholar 

  166. Thomas DA, Cortes J, Giles FJ, Faderl S, O'Brien S, Garcia-Manero G, Pierce S, Keating M, Cabanillas F, Kantarjian H (2001) Rituximab and hyper-CVAD for adult Burkitt's (BL) or Burkitt's-like (BLL) Leukemia or lymphoma. The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:804a, no. 3342

    Google Scholar 

  167. Thomas DA, O'Brien S, Giles F, Cortes J, Faderl S, Kantarjian H, Lerner S, Kurzrock R, Keating M (2001) Single agent Rituxan in early stage chronic lymphocytic leukemia (CLL). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:364a, no. 1533

    Google Scholar 

  168. Tian J, Ding Y, Zhang J, Cao L, Yin D (2000) Fractionated radioimmunotherapy using low doses of iodine-131 labeled anti-CEA monoclonal antibody after tumor volume reduction. Chin Med J (Engl) 113:53–58

    Google Scholar 

  169. Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Lin B, Kimby E, Anderson K C,Byrd J C (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 24(3): 272–279.

    Article  CAS  Google Scholar 

  170. Treon SP, Belch AR, Grossbard ML, Schlossman RL, Ellman L, Harmon D, Doss DS, Preffer FI, Kelliher AS, Pilarski LM, Anderson KC (2000) Phase II study of single agent rituximab in previously treated multiple myeloma patients: patients with CD20+ BM plasma cells may derive benefit from rituximab. Blood 11:164a

    Google Scholar 

  171. Treon SP, Emmanouilides CE, Kimby E, Kelliher A, Preffer F, Freeman A, Mitsiades CS, Mitsiades N, Ainsley S, Fernando D, Anderson K, Frankel SR (2002) Extended rituximab therapy is highly effective and facilitates hematological recovery in patients with lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia, WM). The 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, 18–21 May, 21:268a, no. 1068

  172. Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung N-V, Larson SM (1996) Comparison of the targeting characteristics of various radiommunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. Nucl Med Biol 23:1–8

    Article  CAS  PubMed  Google Scholar 

  173. Valentine MA, Licciardi KA (1992) Rescue from anti-IgM-induced programmed cell death by the B cell surface proteins CD20 and CD40. Eur J Immunol 22:3141–3148

    CAS  PubMed  Google Scholar 

  174. Veatch AL, Smith BE, Maloney DG (2001) Synergy between rituximab and glucocorticoids in vitro. Proc Am Soc Clin Oncol, San Francisco, 20:274a, no. 1094

  175. Venugopal P, Wooldridge JE, Yunus F, Hari P, Gregory S, Alder SS, Enschede SH, O'Brien T, O'Donnell K, Woock S (2001) Phase II study of rituximab in combination with CHOP chemotherapy and GMCSF (leukine) in patients with previously untreated diffuse large cell lymphoma (DLCL) and mantle cell lymphoma (MCL). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:251b, no. 4736

    Google Scholar 

  176. Vitolo U, Boccomini C, Astolfi M, Bertini M, Botto M, Calvi R, Darbesio A, Celle PF di, Freilone R, Godio L, Ladetto M, Novero D, Orsucci L, Pregno P, Palestro G, Gallo E (2001) Chemoimmunotherapy with fludarabine+mitoxantrone+dexamethasone (FND) and rituximab in indolent non-Hodgkin's lymphoma (NHL): a pilot study to evaluate feasibility, safety, clinical and molecular response. The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:251b–252b, no. 4737

    Google Scholar 

  177. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-López A, Gilman P, Lowe A, Kunkel LA, Fisher RI (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389–397

    CAS  PubMed  Google Scholar 

  178. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316–1323

    CAS  PubMed  Google Scholar 

  179. Vriesendorp HM, Quadri SM, Stinson RL, Onyekwere OC, Shao Y, Klein JL, Leichner PK, Williams JR (1992) Selection of reagents for human radioimmunotherapy. Int J Radiat Oncol Biol Phys 22:37–45

    CAS  PubMed  Google Scholar 

  180. Wahl RL (1994) Experimental radioimmunotherapy. A brief overview. Cancer (Suppl) 73:989–992

  181. Walewski J, Kraszewska E, Mioduszewska O, Romejko-Jarosinska J, Hellmann A, Czyz J, Holowiecki J, Kopera M, Grosicki S, Komarnicki M, Rumianowski L, Kuliczkowski K, Wrobel T, Dwilewicz-Trojaczek J, Robak T, Warzocha K, Zaluski J, Wojcik E, Dmoszynska A, Walter-Croneck A (2001) Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol 18:141–148

    CAS  PubMed  Google Scholar 

  182. Washburn LC, Sun TTH, Lee Y-CC, Byrd BL, Holloway EC, Crook JE, Stubbs JB, Stabin MG, Brechbiel MW, Gansow OA, Steplewski Z (1991) Comparison of five bifunctional chelate techniques for90y-labeled monoclonal antibody CO17–1A. Nucl Med Biol 18:313–321

    CAS  Google Scholar 

  183. Wessels BW, Rogus RD (1984) Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 11:637–645

    Google Scholar 

  184. Wierda W, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreef M, Cortes J, Faderl S, Thomas D, Koller C, Kantarjian H, Keating M (2001) Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission as initial treatment of chronic lymphocytic leukemia. The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:771a, no. 3210

    Google Scholar 

  185. Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML (2002) The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29 (Suppl 2):41–47

    Article  CAS  Google Scholar 

  186. Wilson WH, Pittaluga S, O'Connor P, Upendra H, Drbohlav N, Janik J, Little R, Steinberg S, Cheson B, Staudt L, Raffeld M, Chabner B, Jaffe ES (2001) Rituximab may overcome bcl-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphomas. The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:343a, no. 1447

    Google Scholar 

  187. Wiseman GA, Gordon L, Multani PS, Witzig TE, Spies S, Bartlett N, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336–4342

    CAS  PubMed  Google Scholar 

  188. Witzig TE (2000) The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma. Semin Oncol 27 (Suppl 12):74–78

    Google Scholar 

  189. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani PS, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453–2463

    Google Scholar 

  190. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-López AJ (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793–3803

    CAS  PubMed  Google Scholar 

  191. Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD (1998) Stepwise in vitro affinity maturation of Vitaxin, an alpha beta3-specific humanized mAb. Proc Natl Acad Sci USA 95:6037–6042

    Article  CAS  PubMed  Google Scholar 

  192. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning J, Medeiros LJ, Martinez RF, Cabanillas F (2001) Depletion of normal B-lymphocytes by rituximab therapy alters serum cytokine levels, resolves B-symptoms and induces clinical remissions in patients with relapsed classical Hodgkin's disease (HD). The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:132a, no. 555

    Google Scholar 

  193. Zecca M, Stefano P de, Nobili B, Locatelli F (2001) Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 97:3995–3997

    Article  CAS  PubMed  Google Scholar 

  194. Zinzani PL (2001) A randomized trial of fludarabine and mitoantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma. The 43rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7–11 December. Blood 98:842a, no. 3500

    Google Scholar 

  195. Anolik JH, Campbell D, Ritchlin C, Holyst M, Rosenfeld S, Varnis C et al. (2001) B lymphocyte depletion as a novel treatment for systemic lupus erythematosus (SLE): phase I/II trial of rituximab (Rituxan) in SLE. Arthritis Rheum 44:S387

    Google Scholar 

  196. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262–3269

    Article  CAS  PubMed  Google Scholar 

  197. Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883–888

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IDEC Pharmaceuticals Corporation, 3010 Science Park Road, 92121, San Diego, California , USA

    Paul Chinn, Gary Braslawsky, Christine White & Nabil Hanna

Authors
  1. Paul Chinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary Braslawsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine White
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nabil Hanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nabil Hanna.

Additional information

This article forms part of the Symposium in Writing on "Antibodies in Cancer Immunotherapy", published in this issue (Vol. 52) of the journal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chinn, P., Braslawsky, G., White, C. et al. Antibody therapy of non-Hodgkin's B-cell lymphoma. Cancer Immunol Immunother 52, 257–280 (2003). https://doi.org/10.1007/s00262-002-0347-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-002-0347-6

Keywords

Search

Navigation